We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Affitech Contracts with ProBioGen for Producer Cell Line Generation for Oncology Antibody Candidate
News

Affitech Contracts with ProBioGen for Producer Cell Line Generation for Oncology Antibody Candidate

Affitech Contracts with ProBioGen for Producer Cell Line Generation for Oncology Antibody Candidate
News

Affitech Contracts with ProBioGen for Producer Cell Line Generation for Oncology Antibody Candidate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affitech Contracts with ProBioGen for Producer Cell Line Generation for Oncology Antibody Candidate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProBioGen AG, and Affitech AS, have jointly announced that they have entered into an agreement for a biopharmaceutical cell line to be developed by ProBioGen for high-level production of one of the lead candidates in Affitech’s oncology therapeutic antibody pipeline.

Under the terms of the agreement, ProBioGen will apply its proven cell generation process for biopharmaceutical cell lines relying on the vectors and its pre-optimized CHO starter cell. This will be combined with automated cloning process to identify and develop a high producer line, which should be particularly suitable for a fed-batch development process. Financial details of the agreement have not been disclosed.

“Our unique approach in developing high producer cell lines combined with our royalty free business model is very attractive to our customers and provides them with one of the crucial key features for a successful production process.” said Michael Schlenk, CEO at ProBioGen AG.

Announcing the agreement Dr. Martin Welschof, CEO of Affitech said: "While several of our in-house discovered human antibodies are in various stages of preclinical development, in order to meet the demands of our ambitious development program for oncology antibody therapeutics, we have chosen a partner who offers us a high degree of flexibility and a compatible service-based development model.”

Advertisement